Evidence map›Paper›PMID 30187872›Full record

Trial reportNan fang yi ke da xue xue bao = Journal of Southern Medical University2018

[Efficacy and metabolic safety of long-term treatment with ethinyl oestradiol/cyproterone and desogestrel/ethinyl oestradiol tablets in women with polycystic ovary syndrome].

Jun Zhang, Mi Su, Liangzhi Xu, Zhilan Yang, Weiyao Yin, Ying Nie, Xiaoyong Qiao, Ran Cheng, Yaxian Ma

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 73% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jun ZhangDepartment of Obstetrics and Gynecology, West China Second University Hospital/Institute of Reproductive Endocrinology and Reproductive Regulation, Western Research Institute of West China Second Hospital/Joint Laboratory for Reproductive Medicine, Sichuan University, Chengdu 610041, China.
Mi SuDepartment of Obstetrics and Gynecology, West China Second University Hospital/Institute of Reproductive Endocrinology and Reproductive Regulation, Western Research Institute of West China Second Hospital/Joint Laboratory for Reproductive Medicine, Sichuan University, Chengdu 610041, China.
Liangzhi XuDepartment of Obstetrics and Gynecology, West China Second University Hospital/Institute of Reproductive Endocrinology and Reproductive Regulation, Western Research Institute of West China Second Hospital/Joint Laboratory for Reproductive Medicine, Sichuan University, Chengdu 610041, China.
Zhilan YangDepartment of Obstetrics and Gynecology, West China Second University Hospital/Institute of Reproductive Endocrinology and Reproductive Regulation, Western Research Institute of West China Second Hospital/Joint Laboratory for Reproductive Medicine, Sichuan University, Chengdu 610041, China.
Weiyao YinDepartment of Obstetrics and Gynecology, West China Second University Hospital/Institute of Reproductive Endocrinology and Reproductive Regulation, Western Research Institute of West China Second Hospital/Joint Laboratory for Reproductive Medicine, Sichuan University, Chengdu 610041, China.
Ying NieDepartment of Obstetrics and Gynecology, West China Second University Hospital/Institute of Reproductive Endocrinology and Reproductive Regulation, Western Research Institute of West China Second Hospital/Joint Laboratory for Reproductive Medicine, Sichuan University, Chengdu 610041, China.
Xiaoyong QiaoDepartment of Obstetrics and Gynecology, West China Second University Hospital/Institute of Reproductive Endocrinology and Reproductive Regulation, Western Research Institute of West China Second Hospital/Joint Laboratory for Reproductive Medicine, Sichuan University, Chengdu 610041, China.
Ran ChengDepartment of Obstetrics and Gynecology, West China Second University Hospital/Institute of Reproductive Endocrinology and Reproductive Regulation, Western Research Institute of West China Second Hospital/Joint Laboratory for Reproductive Medicine, Sichuan University, Chengdu 610041, China.
Yaxian MaDepartment of Obstetrics and Gynecology, West China Second University Hospital/Institute of Reproductive Endocrinology and Reproductive Regulation, Western Research Institute of West China Second Hospital/Joint Laboratory for Reproductive Medicine, Sichuan University, Chengdu 610041, China.
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the efficacy and metabolic safety of long-term treatment with ethinyl oestradiol/cyproteroneand desogestrel/ethinyl oestradiol tablets in women with polycystic ovary syndrome (PCOS).

methodsWomen with PCOSfrom West China Second Hospital of Sichuan University enrolled between September, 2011 and August, 2013 were randomlyallocated to receive either ethinyl oestradiol/cyproterone tablets (Group A,

resultsAll the patients had a regular menstrual cycle aftertreatments. Testosterone level, acne score, LH/FSH, ovarian volume, and the number of follicles decreased significantly afterthe treatments without significant differences between the two groups. Significant increases were noted in TG, TCh, LDL, HDL, and AIP, and HDL level in group A as compared with group B (

conclusionsBoth ethinyl oestradiol/cyproterone tablets and desogestrel/ethinyl oestradioltablets can relieve the symptoms of PCOS, but it isadvisable to assess the risk of cardiovascular diseasebefore the treatments.

Indexed as

ChinaCyproteroneDesogestrelDrug Therapy, CombinationEthinyl EstradiolFemaleHumansHypoglycemic AgentsInsulin ResistanceMetforminPolycystic Ovary SyndromeProspective StudiesTabletsCyproteroneDesogestrelEthinyl EstradiolHypoglycemic AgentsMetforminTabletsdesogestrel/ethinyl oestradiol tabletsethinyl oestradiol/cyproterone tabletsmetabolismpolycystic ovarian syndrome

Identifiers

PMID30187872
PMCPMC6744035
OpenAlexW2988085409

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.